Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

162116 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-01

Study Completion Date

2017-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Appropriate use of oral antidiabetic drugs (OADs) including dose-reduction is important for patient's safety in T2DM patients with renal impairment (RI). However, there are insufficient data on dose adjustment in accordance with the prescription pattern and the risk of RI of OADs, in particular Dipeptidyl-peptidase-4 inhibitors, in clinical practice in Japan. Therefore, we will investigate OADs usage conditions and dose selection in T2DM patients with RI in clinical practice in Japan

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

NCT03231709

Type 2 Diabetes Mellitus

COMPLETED PHASE4

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

NCT01720303

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE4

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

NCT02157298

Type 2 Diabetes Mellitus

COMPLETED PHASE4

Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

NCT01275794

Type 2 Diabetes

COMPLETED

A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients

NCT00336310

Diabetes Mellitus, Type 2

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with T2DM

oral antidiabetic drugs

Intervention Type DRUG

OADs usage conditions and dose selection in T2DM patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oral antidiabetic drugs

OADs usage conditions and dose selection in T2DM patients

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with T2DM (ICD code: E11 or E14).
* Patients must have their first prescription (defined as index date\*) for any study drugs between 01/01/2014 and 30/09/2016.
* Patients must have at least 6 months enrolment verified by the presence of any record except for the study drug prescriptions within the database (look back period) prior to the index date for each drug.

Exclusion Criteria

* Patients who were under 40 years at the time of diagnosis of diabetes.
* Patients with record of type 1 diabetes mellitus.
* Patients who prescribed the study drugs during 6 month prior to index date for each drug.
* Patients whose mean visit interval are more than 92 days

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No